Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.52
(
2.91%
)
US TECH 100
23,136.80
(
3.61%
)
Dow Jones
46,341.51
(
2.49%
)
Brent Oil
103.14
(
-5.00%
)
Bitcoin
68,101.93
(
2.10%
)
News Focus
News Focus
Post# of 257323
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122830
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: randychub post# 5249

Wednesday, 12/01/2004 1:32:27 AM

Wednesday, December 01, 2004 1:32:27 AM

Post# of 257323
Re: YMI

>> YMI’s phase 2 results in H&N were similiar to the results seen by erbitux with a smaller radiation doseage. <<

http://biz.yahoo.com/prnews/041130/to053_1.html

In the above YMI press release, it says:

“[TheraCIM] has also demonstrated a superior side-effect profile to functionally equivalent, already approved, EGFr antibody drugs.”

Is the “superior side-effect profile” simply a consequence of lower concomitant radiation, or does this phrase refer to something more than that? T.i.a.

P.S. Does anyone here follow YMI besides drbio and Randy?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up